Molecular mechanism regulating myosin and cardiac functions by ELC

Janine Lossie, Clemens Köhncke, Shokoufeh Mahmoodzadeh, Walter Steffen, Monica Canepari, Manuela Maffei, Martin Taube, Oriane Larchevêque, Philipp Baumert, Hannelore Haase, Roberto Bottinelli, Vera Regitz-Zagrosek, Ingo Morano

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The essential myosin light chain (ELC) is involved in modulation of force generation of myosin motors and cardiac contraction, while its mechanism of action remains elusive. We hypothesized that ELC could modulate myosin stiffness which subsequently determines its force production and cardiac contraction. Therefore, we generated heterologous transgenic mouse (TgM) strains with cardiomyocyte-specific expression of ELC with human ventricular ELC (hVLC-1; TgMhVLC-1) or E56G-mutated hVLC-1 (hVLC-1E56G; TgM E56G). hVLC-1 or hVLC-1E56G expression in TgM was around 39% and 41%, respectively of total VLC-1. Laser trap and in vitro motility assays showed that stiffness and actin sliding velocity of myosin with hVLC-1 prepared from TgMhVLC-1 (1.67 pN/nm and 2.3 μm/s, respectively) were significantly higher than myosin with hVLC-1E56G prepared from TgME56G (1.25 pN/nm and 1.7 μm/s, respectively) or myosin with mouse VLC-1 (mVLC-1) prepared from C57/BL6 (1.41 pN/nm and 1.5 μm/s, respectively). Maximal left ventricular pressure development of isolated perfused hearts in vitro prepared from TgMhVLC-1 (80.0 mmHg) were significantly higher than hearts from TgME56G (66.2 mmHg) or C57/BL6 (59.3 ± 3.9 mmHg). These findings show that ELCs decreased myosin stiffness, in vitro motility, and thereby cardiac functions in the order hVLC-1 > hVLC-1E56G ≈ mVLC-1. They also suggest a molecular pathomechanism of hypertrophic cardiomyopathy caused by hVLC-1 mutations.

Original languageEnglish
Pages (from-to)464-469
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume450
Issue number1
DOIs
Publication statusPublished - Jul 18 2014

Fingerprint

Cardiac Myosins
Myosin Light Chains
Myosins
Transgenic Mice
Stiffness
Ventricular Myosins
Hypertrophic Cardiomyopathy
Ventricular Pressure
Cardiac Myocytes
Actins
Lasers
Assays
Mutation
Modulation
In Vitro Techniques

Keywords

  • Essential myosin light chains
  • In vitro motility
  • Mutations
  • Myosin
  • Stiffness

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Lossie, J., Köhncke, C., Mahmoodzadeh, S., Steffen, W., Canepari, M., Maffei, M., ... Morano, I. (2014). Molecular mechanism regulating myosin and cardiac functions by ELC. Biochemical and Biophysical Research Communications, 450(1), 464-469. https://doi.org/10.1016/j.bbrc.2014.05.142

Molecular mechanism regulating myosin and cardiac functions by ELC. / Lossie, Janine; Köhncke, Clemens; Mahmoodzadeh, Shokoufeh; Steffen, Walter; Canepari, Monica; Maffei, Manuela; Taube, Martin; Larchevêque, Oriane; Baumert, Philipp; Haase, Hannelore; Bottinelli, Roberto; Regitz-Zagrosek, Vera; Morano, Ingo.

In: Biochemical and Biophysical Research Communications, Vol. 450, No. 1, 18.07.2014, p. 464-469.

Research output: Contribution to journalArticle

Lossie, J, Köhncke, C, Mahmoodzadeh, S, Steffen, W, Canepari, M, Maffei, M, Taube, M, Larchevêque, O, Baumert, P, Haase, H, Bottinelli, R, Regitz-Zagrosek, V & Morano, I 2014, 'Molecular mechanism regulating myosin and cardiac functions by ELC', Biochemical and Biophysical Research Communications, vol. 450, no. 1, pp. 464-469. https://doi.org/10.1016/j.bbrc.2014.05.142
Lossie J, Köhncke C, Mahmoodzadeh S, Steffen W, Canepari M, Maffei M et al. Molecular mechanism regulating myosin and cardiac functions by ELC. Biochemical and Biophysical Research Communications. 2014 Jul 18;450(1):464-469. https://doi.org/10.1016/j.bbrc.2014.05.142
Lossie, Janine ; Köhncke, Clemens ; Mahmoodzadeh, Shokoufeh ; Steffen, Walter ; Canepari, Monica ; Maffei, Manuela ; Taube, Martin ; Larchevêque, Oriane ; Baumert, Philipp ; Haase, Hannelore ; Bottinelli, Roberto ; Regitz-Zagrosek, Vera ; Morano, Ingo. / Molecular mechanism regulating myosin and cardiac functions by ELC. In: Biochemical and Biophysical Research Communications. 2014 ; Vol. 450, No. 1. pp. 464-469.
@article{02165a77c4cb4b11b478c12326229605,
title = "Molecular mechanism regulating myosin and cardiac functions by ELC",
abstract = "The essential myosin light chain (ELC) is involved in modulation of force generation of myosin motors and cardiac contraction, while its mechanism of action remains elusive. We hypothesized that ELC could modulate myosin stiffness which subsequently determines its force production and cardiac contraction. Therefore, we generated heterologous transgenic mouse (TgM) strains with cardiomyocyte-specific expression of ELC with human ventricular ELC (hVLC-1; TgMhVLC-1) or E56G-mutated hVLC-1 (hVLC-1E56G; TgM E56G). hVLC-1 or hVLC-1E56G expression in TgM was around 39{\%} and 41{\%}, respectively of total VLC-1. Laser trap and in vitro motility assays showed that stiffness and actin sliding velocity of myosin with hVLC-1 prepared from TgMhVLC-1 (1.67 pN/nm and 2.3 μm/s, respectively) were significantly higher than myosin with hVLC-1E56G prepared from TgME56G (1.25 pN/nm and 1.7 μm/s, respectively) or myosin with mouse VLC-1 (mVLC-1) prepared from C57/BL6 (1.41 pN/nm and 1.5 μm/s, respectively). Maximal left ventricular pressure development of isolated perfused hearts in vitro prepared from TgMhVLC-1 (80.0 mmHg) were significantly higher than hearts from TgME56G (66.2 mmHg) or C57/BL6 (59.3 ± 3.9 mmHg). These findings show that ELCs decreased myosin stiffness, in vitro motility, and thereby cardiac functions in the order hVLC-1 > hVLC-1E56G ≈ mVLC-1. They also suggest a molecular pathomechanism of hypertrophic cardiomyopathy caused by hVLC-1 mutations.",
keywords = "Essential myosin light chains, In vitro motility, Mutations, Myosin, Stiffness",
author = "Janine Lossie and Clemens K{\"o}hncke and Shokoufeh Mahmoodzadeh and Walter Steffen and Monica Canepari and Manuela Maffei and Martin Taube and Oriane Larchev{\^e}que and Philipp Baumert and Hannelore Haase and Roberto Bottinelli and Vera Regitz-Zagrosek and Ingo Morano",
year = "2014",
month = "7",
day = "18",
doi = "10.1016/j.bbrc.2014.05.142",
language = "English",
volume = "450",
pages = "464--469",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Molecular mechanism regulating myosin and cardiac functions by ELC

AU - Lossie, Janine

AU - Köhncke, Clemens

AU - Mahmoodzadeh, Shokoufeh

AU - Steffen, Walter

AU - Canepari, Monica

AU - Maffei, Manuela

AU - Taube, Martin

AU - Larchevêque, Oriane

AU - Baumert, Philipp

AU - Haase, Hannelore

AU - Bottinelli, Roberto

AU - Regitz-Zagrosek, Vera

AU - Morano, Ingo

PY - 2014/7/18

Y1 - 2014/7/18

N2 - The essential myosin light chain (ELC) is involved in modulation of force generation of myosin motors and cardiac contraction, while its mechanism of action remains elusive. We hypothesized that ELC could modulate myosin stiffness which subsequently determines its force production and cardiac contraction. Therefore, we generated heterologous transgenic mouse (TgM) strains with cardiomyocyte-specific expression of ELC with human ventricular ELC (hVLC-1; TgMhVLC-1) or E56G-mutated hVLC-1 (hVLC-1E56G; TgM E56G). hVLC-1 or hVLC-1E56G expression in TgM was around 39% and 41%, respectively of total VLC-1. Laser trap and in vitro motility assays showed that stiffness and actin sliding velocity of myosin with hVLC-1 prepared from TgMhVLC-1 (1.67 pN/nm and 2.3 μm/s, respectively) were significantly higher than myosin with hVLC-1E56G prepared from TgME56G (1.25 pN/nm and 1.7 μm/s, respectively) or myosin with mouse VLC-1 (mVLC-1) prepared from C57/BL6 (1.41 pN/nm and 1.5 μm/s, respectively). Maximal left ventricular pressure development of isolated perfused hearts in vitro prepared from TgMhVLC-1 (80.0 mmHg) were significantly higher than hearts from TgME56G (66.2 mmHg) or C57/BL6 (59.3 ± 3.9 mmHg). These findings show that ELCs decreased myosin stiffness, in vitro motility, and thereby cardiac functions in the order hVLC-1 > hVLC-1E56G ≈ mVLC-1. They also suggest a molecular pathomechanism of hypertrophic cardiomyopathy caused by hVLC-1 mutations.

AB - The essential myosin light chain (ELC) is involved in modulation of force generation of myosin motors and cardiac contraction, while its mechanism of action remains elusive. We hypothesized that ELC could modulate myosin stiffness which subsequently determines its force production and cardiac contraction. Therefore, we generated heterologous transgenic mouse (TgM) strains with cardiomyocyte-specific expression of ELC with human ventricular ELC (hVLC-1; TgMhVLC-1) or E56G-mutated hVLC-1 (hVLC-1E56G; TgM E56G). hVLC-1 or hVLC-1E56G expression in TgM was around 39% and 41%, respectively of total VLC-1. Laser trap and in vitro motility assays showed that stiffness and actin sliding velocity of myosin with hVLC-1 prepared from TgMhVLC-1 (1.67 pN/nm and 2.3 μm/s, respectively) were significantly higher than myosin with hVLC-1E56G prepared from TgME56G (1.25 pN/nm and 1.7 μm/s, respectively) or myosin with mouse VLC-1 (mVLC-1) prepared from C57/BL6 (1.41 pN/nm and 1.5 μm/s, respectively). Maximal left ventricular pressure development of isolated perfused hearts in vitro prepared from TgMhVLC-1 (80.0 mmHg) were significantly higher than hearts from TgME56G (66.2 mmHg) or C57/BL6 (59.3 ± 3.9 mmHg). These findings show that ELCs decreased myosin stiffness, in vitro motility, and thereby cardiac functions in the order hVLC-1 > hVLC-1E56G ≈ mVLC-1. They also suggest a molecular pathomechanism of hypertrophic cardiomyopathy caused by hVLC-1 mutations.

KW - Essential myosin light chains

KW - In vitro motility

KW - Mutations

KW - Myosin

KW - Stiffness

UR - http://www.scopus.com/inward/record.url?scp=84904726536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904726536&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2014.05.142

DO - 10.1016/j.bbrc.2014.05.142

M3 - Article

C2 - 24911555

AN - SCOPUS:84904726536

VL - 450

SP - 464

EP - 469

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -